Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction - PubMed (original) (raw)
. 2008 Mar;294(3):H1298-303.
doi: 10.1152/ajpheart.00765.2007. Epub 2008 Jan 11.
Affiliations
- PMID: 18192226
- DOI: 10.1152/ajpheart.00765.2007
Free article
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction
Shijun Huang et al. Am J Physiol Heart Circ Physiol. 2008 Mar.
Free article
Abstract
Arrhythmia-prone epicardial border zone (EBZ) tissues demonstrate decreased G protein-coupled receptor kinase-2 (GRK2) activity and increased sensitivity to isoproterenol 6-24 h after coronary artery ligation in the dog. We previously demonstrated that the ischemia-mediated decrease in GRK2 in cardiac ischemic tissue was largely blocked by proteasome blockade initiated 1 h before the onset of ischemia, and this was associated with significant cardioprotection against malignant ventricular tachyarrhythmias. For application to clinical circumstances, it is desirable to determine whether a clinical window exists following the onset of ischemia for such a protective effect. The treatment of six dogs with the selective proteasome inhibitor bortezomib 1 h after the surgical induction of left coronary artery ischemia provided 80% (EBZ) and 42% (infarct) protection (by immunoblot) against the loss of GRK2 at 24 h. There was no significant increase of heat shock protein 70(72) in the EBZ of bortezomib-treated animals compared with control. There was a striking absence of rapid (>300 beats/min) and very rapid (>360 beats/min) ventricular triplets that is highly predictive of sudden cardiac deaths (SCDs) during electrocardiogram monitoring of the first 24 h in the bortezomib-treated animals in contrast with nontreated infarcted animals. There were no SCDs in the 6 treated animals (0%) and five SCDs in the 14 control animals (36%). Assay of whole blood proteasome activity demonstrated the expected decrease over the 24-h observation period. These data support the concept that proteasome inhibition within a window of time following myocardial infarction may be of use in suppressing malignant tachyarrhythmias and SCD.
Similar articles
- Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction.
Yu X, Huang S, Patterson E, Garrett MW, Kaufman KM, Metcalf JP, Zhu M, Dunn ST, Kem DC. Yu X, et al. Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H1960-7. doi: 10.1152/ajpheart.00328.2005. Epub 2005 Jul 1. Am J Physiol Heart Circ Physiol. 2005. PMID: 15994860 - Tumor necrosis factor alpha, rapid ventricular tachyarrhythmias, and infarct size in canine models of myocardial infarction.
Yu X, Patterson E, Huang S, Garrett MW, Kem DC. Yu X, et al. J Cardiovasc Pharmacol. 2005 Feb;45(2):153-9. doi: 10.1097/01.fjc.0000151930.12026.b7. J Cardiovasc Pharmacol. 2005. PMID: 15654264 - Ischemic inactivation of G protein-coupled receptor kinase and altered desensitization of canine cardiac beta-adrenergic receptors.
Yu X, Zhang M, Kyker K, Patterson E, Benovic JL, Kem DC. Yu X, et al. Circulation. 2000 Nov 14;102(20):2535-40. doi: 10.1161/01.cir.102.20.2535. Circulation. 2000. PMID: 11076829 - [Effects of proteasome inhibitors on leukemias].
Lü SQ, Yang JM, Wang JM. Lü SQ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Aug;15(4):896-900. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007. PMID: 17708829 Review. Chinese. - [Proteasome inhibitor].
Yamamura M, Hirai T, Yamaguchi Y. Yamamura M, et al. Nihon Rinsho. 2010 Jun;68(6):1079-84. Nihon Rinsho. 2010. PMID: 20535959 Review. Japanese.
Cited by
- Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost.
Efentakis P, Andreadou I, Iliodromitis KE, Triposkiadis F, Ferdinandy P, Schulz R, Iliodromitis EK. Efentakis P, et al. Int J Mol Sci. 2022 Nov 15;23(22):14121. doi: 10.3390/ijms232214121. Int J Mol Sci. 2022. PMID: 36430599 Free PMC article. Review. - Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion.
Penela P, Inserte J, Ramos P, Rodriguez-Sinovas A, Garcia-Dorado D, Mayor F Jr. Penela P, et al. EBioMedicine. 2019 Oct;48:605-618. doi: 10.1016/j.ebiom.2019.09.019. Epub 2019 Oct 5. EBioMedicine. 2019. PMID: 31594751 Free PMC article. - G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases.
Murga C, Arcones AC, Cruces-Sande M, Briones AM, Salaices M, Mayor F Jr. Murga C, et al. Front Pharmacol. 2019 Feb 19;10:112. doi: 10.3389/fphar.2019.00112. eCollection 2019. Front Pharmacol. 2019. PMID: 30837878 Free PMC article. Review. - Partial inhibition of the ubiquitin-proteasome system ameliorates cardiac dysfunction following ischemia-reperfusion in the presence of high glucose.
Adams B, Mapanga RF, Essop MF. Adams B, et al. Cardiovasc Diabetol. 2015 Jul 28;14:94. doi: 10.1186/s12933-015-0258-4. Cardiovasc Diabetol. 2015. PMID: 26216448 Free PMC article. - Cardiac specific expression of threonine 5 to alanine mutant sarcolipin results in structural remodeling and diastolic dysfunction.
Shanmugam M, Li D, Gao S, Fefelova N, Shah V, Voit A, Pachon R, Yehia G, Xie LH, Babu GJ. Shanmugam M, et al. PLoS One. 2015 Feb 11;10(2):e0115822. doi: 10.1371/journal.pone.0115822. eCollection 2015. PLoS One. 2015. PMID: 25671318 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical